P/E ratio for Lipocine (LPCN)
P/E ratio as of April 2025 (TTM): -1.36
According to Lipocine's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.36425. At the end of 2022 the company had a P/E ratio of -3.33.
P/E ratio history for Lipocine from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -3.33 | -96.64% |
| 2021 | -99.1 | 2814.71% |
| 2020 | -3.40 | 341.56% |
| 2019 | -0.7700 | -67.42% |
| 2018 | -2.36 | -28.54% |
| 2017 | -3.31 | -6.52% |
| 2016 | -3.54 | -70.06% |
| 2015 | -11.8 | 259.52% |
| 2014 | -3.29 | -63.46% |
| 2013 | -9.00 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 | -57.0 | 4,081.23% | 🇺🇸 USA |
 | -71.6 | 5,146.44% | 🇮🇪 Ireland |
 | -0.0382 | -97.20% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.